Drugs / GMCN-508B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05762510 | Feb 2023 → Apr 2028 expected | beta thalassemia | First Affiliated Hospital of Guangxi Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMCN-508B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05762510 ↗ |
| Known as | LentiRed | “GMCN-508B (LentiRed)” NCT05762510 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “gene therapy” NCT05762510 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT05762510 ↗ |